Physician profile
Brandon Kellie
NPI 1649413063
$9,436.82
in general payments reported to CMS, 2019-2025
47 companies · $1,679 in 2025
The $1,679 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,541 · 2020: $1,034 · 2021: $1,024 · 2022: $1,123 · 2023: $1,230 · 2024: $1,807 · 2025: $1,679.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,661 · Education: $54.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,661.23 |
| Education | $54.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,095.94 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Pfizer INC. | $1,029.68 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,006.67 | 2019-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Insmed, INC. | $781.03 | 2019-2025 | Arikayce |
| Astrazeneca Pharmaceuticals LP | $725.16 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Mylan Specialty L.P. | $537.86 | 2019-2024 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $458.48 | 2019-2025 | Dupixent |
| Grifols USA, LLC | $450.07 | 2019-2025 | Prolastin-C Liquid |
| Genentech USA, INC. | $336.12 | 2019-2023 | Xolair |
| Merck Sharp & Dohme LLC | $313.79 | 2023-2025 | Winrevair, Zerbaxa, Recarbrio |
| Actelion Pharmaceuticals US, INC. | $286.78 | 2019-2025 | Uptravi, Opsumit |
| Amgen INC. | $261.20 | 2021-2025 | Tezspire, Tavneos |
| Genzyme Corporation | $227.61 | 2020-2024 | |
| Csl Behring | $205.92 | 2021-2025 | Kcentra |
| United Therapeutics Corporation | $171.94 | 2019-2025 | Tyvaso, Tyvaso |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $158.57 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $126.44 | 2021-2025 | Glassia |
| Sunovion Pharmaceuticals INC. | $119.31 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $117.76 | 2020-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $79.00 | 2023-2025 | |
| Baxter Healthcare | $78.53 | 2022-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Monarch Airway Clearance System |
| Mallinckrodt Hospital Products INC. | $77.60 | 2025 | Acthar |
| Teva Pharmaceuticals USA, INC. | $74.53 | 2019-2022 | |
| Viatris Specialty LLC | $74.09 | 2025 | Yupelri |
| Shire North American Group INC | $62.66 | 2019 | |
| Pulmonx Corporation | $62.07 | 2021-2023 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Electromed, INC. | $49.71 | 2021-2024 | Smartvest |
| Pharming Healthcare, INC. | $46.73 | 2023 | Ruconest |
| Janssen Pharmaceuticals, INC | $45.20 | 2019-2022 | |
| Astellas Pharma US INC | $44.94 | 2019 | |
| Paratek Pharmaceuticals, INC. | $43.57 | 2021-2022 | |
| Philips North America LLC | $31.82 | 2019-2022 | |
| Allergan, INC. | $28.50 | 2020 | |
| Verona Pharma, INC. | $28.05 | 2025 | Ohtuvayre |
| Abbott Laboratories | $20.87 | 2022 | |
| Cmp Pharma, INC. | $18.64 | 2023 | Tadliq |
| Lilly USA, LLC | $17.95 | 2025 | Zepbound |
| Avadel Cns Pharmaceuticals, LLC | $16.69 | 2023 | Lumryz |
| Mayne Pharma Commercial LLC | $16.05 | 2021 | |
| Sanofi-Aventis U.S. LLC | $15.08 | 2020 | |
| Resmed Corp | $14.90 | 2022 | |
| Ambu INC. | $14.64 | 2023 | |
| Chiesi USA, INC. | $14.29 | 2019 | |
| Fisher & Paykel Healthcare INC | $14.09 | 2019 | |
| Mallinckrodt Enterprises LLC | $14.02 | 2019 | |
| Gilead Sciences, INC. | $11.76 | 2019 | |
| Inogen, INC. | $10.51 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandon Kellie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.